Cautious Hold Rating on Globus Medical Amid Supply Chain Challenges and Nevro Acquisition Uncertainty

Needham analyst David Saxon has maintained their neutral stance on GMED stock, giving a Hold rating today.

David Saxon has given his Hold rating due to a combination of factors impacting Globus Medical’s performance. The company’s first-quarter revenue and earnings per share for 2025 fell short of expectations, primarily because of supply chain issues, timing of international orders, and weaker performance in their Enabling Technology segment.
Although these challenges are mostly resolved, the recent acquisition of Nevro introduces some uncertainty regarding future financial projections. As a result, Saxon maintains a cautious outlook, opting for a Hold rating to reflect the potential risks and uncertainties associated with the integration of Nevro and its impact on Globus Medical’s long-term growth prospects.

In another report released today, Bank of America Securities also reiterated a Hold rating on the stock with a $78.00 price target.